Comparison · NCT04865289-a59991bb
Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Experiencing a Serious Adverse Event (SAE)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Experiencing a Serious Adverse Event (SAE). Trial comparisons, record NCT04865289-a59991bb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04865289-a59991bb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.548 | 0.434 | 0.657 | wilson | |
| Risk in group 2 | 0.304 | 0.199 | 0.433 | wilson | |
| Risk difference, group 1 minus group 2 | 0.244 | 0.0718 | 0.395 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.8 | 1.15 | 2.83 | log | |
| Odds ratio, group 1 over group 2 | 2.78 | 1.34 | 5.79 | log | |
| Number needed to treat, for one more participant with the outcome on Lenvatinib + Pembrolizumab than on Paclitaxel + Carboplatin | 4.09 | 2.53 | 13.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lenvatinib + Pembrolizumab | Participants received lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle. | 40 | 73 | OG000 |
| Group 2 | Paclitaxel + Carboplatin | Participants received paclitaxel and carboplatin once at the start of each 3-week treatment cycle. | 17 | 56 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Experiencing a Serious Adverse Event (SAE)
- Description
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE is an AE that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability, is a congenital birth defect, or is another important medical event.
- Time frame
- From first dose date to 120 days after last dose date (up to approximately 58 months)
- Population
- All Chinese participants who were randomized to the global study (NCT03884101) and to the extension portion and received at least one dose of the study intervention were analyzed
Source ClinicalTrials.gov
Trial
- Title
- Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
- NCT number
- NCT04865289
- Phases
- PHASE3
- Conditions
- Endometrial Neoplasms
- Interventions
- Lenvatinib, Pembrolizumab, Paclitaxel, Carboplatin
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2024-10-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04865289?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04865289-a59991bb